BIOMAT Database Logo BIOMAT Database Logo

Evolution of clinical studies with high-dose cytosine arabinoside at the M.D. Anderson Hospital. 1985

M J Keating, and E Estey, and W Plunkett, and S Iacoboni, and R Walters, and H Kantarjian, and B Andersson, and M Beran, and K B McCredie, and E J Freireich

UI MeSH Term Description Entries
D007938 Leukemia A progressive, malignant disease of the blood-forming organs, characterized by distorted proliferation and development of leukocytes and their precursors in the blood and bone marrow. Leukemias were originally termed acute or chronic based on life expectancy but now are classified according to cellular maturity. Acute leukemias consist of predominately immature cells; chronic leukemias are composed of more mature cells. (From The Merck Manual, 2006) Leucocythaemia,Leucocythemia,Leucocythaemias,Leucocythemias,Leukemias
D007945 Leukemia, Lymphoid Leukemia associated with HYPERPLASIA of the lymphoid tissues and increased numbers of circulating malignant LYMPHOCYTES and lymphoblasts. Leukemia, Lymphocytic,Lymphocytic Leukemia,Lymphoid Leukemia,Leukemias, Lymphocytic,Leukemias, Lymphoid,Lymphocytic Leukemias,Lymphoid Leukemias
D007951 Leukemia, Myeloid Form of leukemia characterized by an uncontrolled proliferation of the myeloid lineage and their precursors (MYELOID PROGENITOR CELLS) in the bone marrow and other sites. Granulocytic Leukemia,Leukemia, Granulocytic,Leukemia, Myelocytic,Leukemia, Myelogenous,Myelocytic Leukemia,Myelogenous Leukemia,Myeloid Leukemia,Leukemia, Monocytic, Chronic,Monocytic Leukemia, Chronic,Chronic Monocytic Leukemia,Chronic Monocytic Leukemias,Granulocytic Leukemias,Leukemia, Chronic Monocytic,Leukemias, Chronic Monocytic,Leukemias, Granulocytic,Leukemias, Myelocytic,Leukemias, Myelogenous,Leukemias, Myeloid,Monocytic Leukemias, Chronic,Myelocytic Leukemias,Myelogenous Leukemias,Myeloid Leukemias
D011379 Prognosis A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations. Prognostic Factor,Prognostic Factors,Factor, Prognostic,Factors, Prognostic,Prognoses
D002869 Chromosome Aberrations Abnormal number or structure of chromosomes. Chromosome aberrations may result in CHROMOSOME DISORDERS. Autosome Abnormalities,Cytogenetic Aberrations,Abnormalities, Autosome,Abnormalities, Chromosomal,Abnormalities, Chromosome,Chromosomal Aberrations,Chromosome Abnormalities,Cytogenetic Abnormalities,Aberration, Chromosomal,Aberration, Chromosome,Aberration, Cytogenetic,Aberrations, Chromosomal,Aberrations, Chromosome,Aberrations, Cytogenetic,Abnormalities, Cytogenetic,Abnormality, Autosome,Abnormality, Chromosomal,Abnormality, Chromosome,Abnormality, Cytogenetic,Autosome Abnormality,Chromosomal Aberration,Chromosomal Abnormalities,Chromosomal Abnormality,Chromosome Aberration,Chromosome Abnormality,Cytogenetic Aberration,Cytogenetic Abnormality
D003561 Cytarabine A pyrimidine nucleoside analog that is used mainly in the treatment of leukemia, especially acute non-lymphoblastic leukemia. Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA. Its actions are specific for the S phase of the cell cycle. It also has antiviral and immunosuppressant properties. (From Martindale, The Extra Pharmacopoeia, 30th ed, p472) Ara-C,Arabinofuranosylcytosine,Arabinosylcytosine,Cytosine Arabinoside,Aracytidine,Aracytine,Cytarabine Hydrochloride,Cytonal,Cytosar,Cytosar-U,beta-Ara C,Ara C,Arabinoside, Cytosine,Cytosar U,beta Ara C
D004341 Drug Evaluation Any process by which toxicity, metabolism, absorption, elimination, preferred route of administration, safe dosage range, etc., for a drug or group of drugs is determined through clinical assessment in humans or veterinary animals. Evaluation Studies, Drug,Drug Evaluation Studies,Drug Evaluation Study,Drug Evaluations,Evaluation Study, Drug,Evaluation, Drug,Evaluations, Drug,Studies, Drug Evaluation,Study, Drug Evaluation
D004351 Drug Resistance Diminished or failed response of an organism, disease or tissue to the intended effectiveness of a chemical or drug. It should be differentiated from DRUG TOLERANCE which is the progressive diminution of the susceptibility of a human or animal to the effects of a drug, as a result of continued administration. Resistance, Drug
D006207 Half-Life The time it takes for a substance (drug, radioactive nuclide, or other) to lose half of its pharmacologic, physiologic, or radiologic activity. Halflife,Half Life,Half-Lifes,Halflifes
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

M J Keating, and E Estey, and W Plunkett, and S Iacoboni, and R Walters, and H Kantarjian, and B Andersson, and M Beran, and K B McCredie, and E J Freireich
[High-dose cytosine arabinoside].
February 1985, Onkologie,
M J Keating, and E Estey, and W Plunkett, and S Iacoboni, and R Walters, and H Kantarjian, and B Andersson, and M Beran, and K B McCredie, and E J Freireich
High-dose cytosine arabinoside: pharmacological and clinical aspects.
January 1988, Blut,
M J Keating, and E Estey, and W Plunkett, and S Iacoboni, and R Walters, and H Kantarjian, and B Andersson, and M Beran, and K B McCredie, and E J Freireich
Cerebellar toxicity with high-dose cytosine arabinoside.
June 1987, Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
M J Keating, and E Estey, and W Plunkett, and S Iacoboni, and R Walters, and H Kantarjian, and B Andersson, and M Beran, and K B McCredie, and E J Freireich
Gastroparesis associated with high-dose cytosine arabinoside.
February 2008, Internal medicine journal,
M J Keating, and E Estey, and W Plunkett, and S Iacoboni, and R Walters, and H Kantarjian, and B Andersson, and M Beran, and K B McCredie, and E J Freireich
Neurotoxicity of high-dose cytosine arabinoside.
January 1985, Progress in experimental tumor research,
M J Keating, and E Estey, and W Plunkett, and S Iacoboni, and R Walters, and H Kantarjian, and B Andersson, and M Beran, and K B McCredie, and E J Freireich
[Results of therapy with high-dose cytosine arabinoside].
February 1985, Onkologie,
M J Keating, and E Estey, and W Plunkett, and S Iacoboni, and R Walters, and H Kantarjian, and B Andersson, and M Beran, and K B McCredie, and E J Freireich
High-dose cytosine arabinoside-associated pancreatitis.
October 1985, Cancer,
M J Keating, and E Estey, and W Plunkett, and S Iacoboni, and R Walters, and H Kantarjian, and B Andersson, and M Beran, and K B McCredie, and E J Freireich
Pharmacologic studies of low-dose and high-dose continuous infusion cytosine arabinoside.
June 1987, Seminars in oncology,
M J Keating, and E Estey, and W Plunkett, and S Iacoboni, and R Walters, and H Kantarjian, and B Andersson, and M Beran, and K B McCredie, and E J Freireich
Neurotoxicity associated with systemic high-dose cytosine arabinoside.
April 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
M J Keating, and E Estey, and W Plunkett, and S Iacoboni, and R Walters, and H Kantarjian, and B Andersson, and M Beran, and K B McCredie, and E J Freireich
Anterior uveitis associated with high-dose cytosine arabinoside.
December 2010, Ocular immunology and inflammation,
Copied contents to your clipboard!